As Trump targets DEI practices, 4 pharmas reaffirm commitment to diversifying clinical trials
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion initiatives in the government and beyond, several large drugmakers say running diverse clinical trials is not optional or extraneous, but a core part of the work they do.
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion initiatives in the government and beyond, several large drugmakers say running diverse clinical trials is not optional or extraneous, but a core part of the work they do.
